Comparative Pharmacology
Head-to-head clinical analysis: DROSPIRENONE ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM versus NORETHINDRONE AND MESTRANOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROSPIRENONE ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM versus NORETHINDRONE AND MESTRANOL.
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM vs NORETHINDRONE AND MESTRANOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of drospirenone (a progestin with antimineralocorticoid and antiandrogenic activity), ethinyl estradiol (an estrogen), and levomefolate calcium (a folate supplement). Prevents ovulation by suppressing gonadotropins; increases cervical mucus viscosity, inhibiting sperm penetration; levomefolate provides folate to reduce neural tube defect risk.
Norethindrone is a progestin that suppresses gonadotropin secretion, primarily luteinizing hormone (LH), thereby inhibiting ovulation. Mestranol is a prodrug of ethinyl estradiol, an estrogen that provides negative feedback on the hypothalamic-pituitary-ovarian axis, further suppressing follicle-stimulating hormone (FSH) and LH. The combination stabilizes the endometrium and alters cervical mucus consistency to impede sperm penetration.
One tablet orally once daily for 28 days (21 active tablets containing drospirenone 3 mg, ethinyl estradiol 0.02 mg, and levomefolate calcium 0.451 mg, followed by 7 placebo tablets containing levomefolate calcium 0.451 mg).
1 tablet (norethindrone 1 mg / mestranol 0.05 mg) orally once daily for 21 days, then 7 days off.
None Documented
None Documented
Drospirenone: ~30 hours (steady state achieved after 8 days). Ethinyl estradiol: ~13-17 hours (biphasic, terminal). Levomefolate calcium: ~4-6 hours (folate derivatives have longer retention).
Norethindrone: 5-12 hours; Mestranol: 50-120 minutes (mestranol is rapidly demethylated to ethinyl estradiol, which has a half-life of 10-20 hours). Clinical context: Steady-state is achieved within 5-7 days; no clinically significant accumulation under normal dosing.
Drospirenone: ~50% renal (as metabolites), ~40% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal. Levomefolate calcium: ~70% renal (as folate metabolites), ~30% fecal.
Renal (30-50% as metabolites), biliary/fecal (35-55% as metabolites and conjugated forms).
Category D/X
Category D/X
Progestin + Estrogen
Progestin